Objective: The study aimed to investigate the antidiabetic effect of ethyl acetate fraction of seed of Eugenia jambolana (E. jambolana) at genomic level in streptozotocin (STZ) induced diabetic male albino rat.
Methods: Diabetic rats were treated with said fraction at the dose of 200 mg/Kg of body weight/day for 35 days. Potential antidiabetic mechanisms were investigated with blood glucose (short duration and long duration model), serum insulin, haemoglobin A1C (HbA1C), ISEL (In-Situ End Labelling) study of pancreatic tissue and quantitative RT-PCR study of hepatic hexokinase-I (Hex-I), Bax and Bcl-2 gene expression.
Results: Results showed a significant antihyperglycemic action of the said fraction in both short and long duration treatment schedule. Serum insulin and HbA1C levels were also recovered in treated group in compare to the untreated diabetic group (p<0.05). ISEL study focused the regeneration of pancreatic beta cells in treated group. It was also observed that the correction in expression in Bax, Bcl-2 and Hex-I gene in hepatic tissue after the treatment of the fraction in the diabetic rat. The antidiabetic activity of the fraction was compared with glibenclamide, a standard antidiabetic drug.
Conclusion: The findings provide information about the antihyperglycemic activity of this fraction through gene regulation
